Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1

By sjmartinez • August 30, 2023

Schwarzer A, Oliveira M, Kleppa MJ, Slattery SD, Anantha A, Cooper A, Hannink M, Schambach A, Doerrie A, Kotylarov A, Gaestel M, Hembrough T, Levine J, Luther M, Stocum M, Stiles L, Weinstock DM, Liesa M, Kostura MJ. Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1. Mol Cancer Ther. 2023 Aug 30. doi: 10.1158/1535-7163.MCT-22-0718. Epub ahead of print. PMID: 37643767.

Tags: Endocrinology, Publications

A Bridge Too Far? Towards Medical Therapy for Clinically Nonfunctioning Pituitary Tumors

Mogar N, Zhang D, Heaney AP. A Bridge Too Far? Towards Medical Therapy for Clinically Nonfunctioning Pituitary Tumors. Int J Mol Sci. 2025 Jun 19;26(12):5898.[...]

Metabolic Messengers: oestradiol

Hevener AL, Correa SM. Metabolic Messengers: oestradiol. Nat Metab. 2025 Jun;7(6):1114-1122. doi: 10.1038/s42255-025-01317-7. Epub 2025 Jun 24. PMID: 40562968.

Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer

LeVee A, Peluso E, Lechner MG, Ruel N, Mortimer J, Kang I, Tsai K. Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in[...]